Ruben Dario
Ruben Dario Ochoa Vivanco, Col. El Prado MX
Patent application number | Description | Published |
---|---|---|
20080245992 | Mixture of Refrigerant Gases Based on Hydrocarbons in Order to Obtain Greater Efficiency in Air Conditioning and Refrigeration Compression Systems - The invention relates to the mixture of natural gases based on hydrocarbons (HC) which do not damage the ozone layer and which have an insignificant greenhouse effect, said gases being substitutes for CFC gases R-12 and R-22, whereby the R-12 substitute is known as HC-12 and the R-22 substitute is known as HC-22. The aforementioned mixtures, which generate a specific pressure/temperature curve, improve the efficiency of air conditioning and refrigeration compression systems. Specifically, since condensation pressures are lower, less pressure and, consequently, less work is required from the compressor, and hence power consumption is reduced. In addition, the refrigerant gases, based on HC mixtures, replace CFCs and HCFCs and are compatible with materials and elements used in commercial refrigeration and air conditioning systems. The resulting mixture generates a specific pressure/temperature curve with a range of plus or minus 5%. Said refrigerant gases, based on HC mixtures, replace alternative refrigerants comprising mixtures containing large amounts of HFCs (hydrofluorocarbons) and are compatible with materials and elements used in commercial refrigeration and air conditioning systems. | 10-09-2008 |
Ruben Dario Rodriguez Quintero, Aberdeen GB
Patent application number | Description | Published |
---|---|---|
20100021980 | HYBRID PROCESS FOR THE PRODUCTION OF BIOFUEL - A method of producing a biofuel from biomass is provided. In one embodiment, the biofuel production process is an ethanol production process. Various embodiments of the invention include features such as application of a shock wave to biomass, variations in composition of biomass feed stock, continuous fermentation, and anaerobic digestion of stillage to produce a methane based fuel. | 01-28-2010 |
20130015405 | ISOTHERMAL REACTOR FOR PARTIAL OXIDATION OF METHANEAANM Quintero; Ruben Dario RodriguezAACI AberdeenAACO GBAAGP Quintero; Ruben Dario Rodriguez Aberdeen GBAANM Diaz; Ernesto Manuel SantanaAACI AberdeenAACO GBAAGP Diaz; Ernesto Manuel Santana Aberdeen GBAANM Banister; James AndrewAACI AberdeenAACO GBAAGP Banister; James Andrew Aberdeen GB - There is herein described a process and apparatus for partial oxidation of hydrocarbons. More particularly, there is described a process and an isothermal reactor apparatus for the partial oxidation of methane which comprises a heat transfer surface, a porous catalytic membrane and wherein heat is disipated and/or removed through the heat transfer surface. | 01-17-2013 |
20130032762 | APPARATUS AND METHOD FOR ADIABATIC METHANE CONVERSION - There is herein described a process and apparatus for hydrocarbon conversion. More particularly, there is described a process and apparatus for adiabatic methane conversion into synthetic gas (i.e. syngas). | 02-07-2013 |
Ruben Dario Sinisterra Milan, Ouro Preto-Mg BR
Patent application number | Description | Published |
---|---|---|
20090270495 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof - We disclose substances and a process of developing such substances as potent and selective inhibitors of isoforms of phosphodiesterases of types 1 to 5 (PDE1, PDE2, PDE3, PDE4, PDE5) based on two flavonoids: dioclein, floranol and natural or synthetic analogs thereof. They may be associated with cyclodextrins in inclusion complexes or using a biodegradable or non-biodegradable polymer, such as PLGA, PLA, PGA or mixtures thereof in controlled release devices. Their respective pharmaceutical compositions as well as pharmaceutical and pharmacologically acceptable excipients may be used for the study and treatment of cardiovascular diseases and associated products. | 10-29-2009 |
Ruben Dario Sinisterra Millan, Bello Horizonte BR
Patent application number | Description | Published |
---|---|---|
20090005303 | PROTEASES FROM CARICA HAVING MITOGENIC ACTIVITY AND THEIR METHODS OF USE - Proteases having mitogenic activity isolated from the genus | 01-01-2009 |
Rubén Dario Sinisterra Millan, Belo Horizonte BR
Patent application number | Description | Published |
---|---|---|
20130164341 | PREPARATION OF FORMULATIONS OF ANGIOTENSIN II AT1 RECEPTORS ANTAGONISTS FOR THE TREATMENT OF ARTERIAL HYPERTENSION, OTHER CARDIOVASCULAR ILLNESSES AND ITS COMPLICATIONS - Inclusion compounds consisting of certain Angiotensin II AT1 receptor antagonists and cyclodextrins are described. These inclusion compounds are useful in the treatment of hypertension. | 06-27-2013 |
Rubén Dario Sinisterramillán, Belo Horizente Mg BR
Patent application number | Description | Published |
---|---|---|
20100144624 | PROCESS FOR THE PREPARATION OF COMPOSITIONS OF AT1 RECEPTOR ANTAGONIST AND ANGIOTENSIN-(1-7) - We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus. They may also be used in the study and therapy of cardiovascular, renal, reproductive, dermatological, neoplastic, blood and cerebral diseases, and when formulated in controlled release systems, encapsulated or not in cyclodextrins, for use in stent, with a view to modulate the growth of the neointima after catheterization procedures. | 06-10-2010 |
Rubén Dario Sinisterramillán, Belo Horizente Mg BR
Patent application number | Description | Published |
---|---|---|
20100144624 | PROCESS FOR THE PREPARATION OF COMPOSITIONS OF AT1 RECEPTOR ANTAGONIST AND ANGIOTENSIN-(1-7) - We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus. They may also be used in the study and therapy of cardiovascular, renal, reproductive, dermatological, neoplastic, blood and cerebral diseases, and when formulated in controlled release systems, encapsulated or not in cyclodextrins, for use in stent, with a view to modulate the growth of the neointima after catheterization procedures. | 06-10-2010 |
Rubén Dario Sinisterra Millán, Belo Horizonte Mg BR
Ruben Darío Artero Allepuz, Valencia ES
Patent application number | Description | Published |
---|---|---|
20130143825 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF TOXIC TRANSCRIPTS - Compounds to be used in the treatment of diseases based on the expression of toxic transcripts. The present invention relates to peptide molecules, specifically hexapeptides, designed for the prevention and/or treatment of diseases the etiology whereof is based on the presence of toxic transcripts that comprise CUG, CCUG, CGG, CAG and AAG repeats, preferably: DM1 SCA8, DM2, FXTAS, HD and FA. | 06-06-2013 |
Ruben Darío Artero Allepuz, Valencia ES
Patent application number | Description | Published |
---|---|---|
20130143825 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF TOXIC TRANSCRIPTS - Compounds to be used in the treatment of diseases based on the expression of toxic transcripts. The present invention relates to peptide molecules, specifically hexapeptides, designed for the prevention and/or treatment of diseases the etiology whereof is based on the presence of toxic transcripts that comprise CUG, CCUG, CGG, CAG and AAG repeats, preferably: DM1 SCA8, DM2, FXTAS, HD and FA. | 06-06-2013 |
Ruben Darío Godoy Silva, Bogota CO
Patent application number | Description | Published |
---|---|---|
20150368587 | REACTION SYSTEM FOR PRODUCING FATTY ALKYL ESTERS USING A LIQUID-FILM REACTOR OPERATED COUNTERCURRENTWISE - The present invention discloses a reaction system for producing fatty-acid alkyl esters using packed reactors, particularly liquid-film reactors, with a countercurrent feed current flow scheme based on the alcoholysis of oils and fats, specifically the methanolysis of palm oil and soya oil. The reaction system comprises a descending liquid-film reactor that uses as semi-structured packing for generating an interface area. The reactor is fed, separately, with the oil or fat, through the bottom of the reactor, and a mixture containing alcohol, glycerol and catalyst, which may be fed in in an intermediate stage. It is also possible, optionally, to feed in a second stream of the mixture of alcohol, glycerol and catalyst in proportions different from those of the first stream, either in an intermediate stage of the reactor or through the top thereof. The products, a mixture of fatty-acid alkyl esters, alcohol and catalyst, and another of glycerol, alcohol and catalyst, exit via the top and the bottom of the reactor, respectively. The volumetric fraction of packing in the reactor is between 2 and 50%, the operating temperature between 25° C. and 180° C., depending on the alcohol used, the molar ratio of alcohol to oil or fat between 3:1 and 10:1, and it is possible for the catalyst to be any homogeneous basic catalyst used in alcoholysis, such as CH3OK, NaOH, KOH, or mixtures thereof, in a proportion of between 0.5% and 3% by weight with respect to the oil flow. The conversion and the yield of the liquid-film reactor operated countercurrentwise, in a single reaction step, are greater than 99.7% and 99.9%, respectively. | 12-24-2015 |